|
Prior capecitabine vs. no prior capecitabine
|
1.50
|
1.12-2.02
|
0.0072
|
1.33
|
0.97-1.83
|
0.0790
|
1.22
|
0.89-1.67
|
0.2140
|
0.73
|
0.48-1.10
|
0.1351
|
|
Hormone receptor positive vs. hormone receptor negative
|
0.78
|
0.57-1.06
|
0.1064
|
0.80
|
0.57-1.11
|
0.1741
| | | | | | |
|
Best systemic response SD, PD vs. CR, PR
|
2.54
|
1.85-3.48
|
<0.0001
|
1.88
|
1.33-2.64
|
0.0003
|
2.60
|
1.87-3.63
|
<0.0001
|
1.31
|
0.86-1.99
|
0.2064
|
|
Median prior trastuzumab duration, wks ≥24.1 vs. <24.1
|
0.68
|
0.50-0.91
|
0.0108
|
0.57
|
0.41-0.78
|
0.0006
|
0.66
|
0.48-0.89
|
0.0074
|
0.68
|
0.48-0.96
|
0.0271
|
|
Age ≥50 vs. <50
|
0.89
|
0.66-1.20
|
0.4418
|
0.84
|
0.61-1.15
|
0.2726
| | | | | | |
|
No. of metastasis ≥3 vs. <3
|
1.16
|
0.86-1.16
|
0.3427
|
1.64
|
1.18-2.28
|
0.0034
| | | |
1.78
|
1.23-2.58
|
0.0023
|
|
No. of prior chemotherapy regimens >3 vs. ≤3
|
1.17
|
0.86-1.58
|
0.3214
|
1.58
|
1.14-2.19
|
0.0067
| | | |
1.64
|
1.08-2.47
|
0.0194
|
|
Pattern of metastasis Visceral only vs. other
|
1.58
|
1.17-2.15
|
0.0031
|
0.98
|
0.70-1.36
|
0.8928
|
1.61
|
1.18-2.21
|
0.0031
| | | |
|
Median TTP, wks ≥20.0 vs. <20.0
| | | |
0.36
|
0.26-0.50
|
<0.0001
| | | |
0.37
|
0.25-0.56
|
<0.0001
|
|
Brain metastasis vs. no brain metastasis
|
0.98
|
0.71-1.35
|
0.8979
|
1.23
|
0.88-1.74
|
0.2310
| | | | | | |
